LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
692
via finance.yahoo.comBusiness & Companies

Second Phase 3 Caplyta bipolar mania trial meets endpoints

FROM THE WIRE · FINANCE.YAHOO.COM

Johnson & Johnson reported that its second pivotal Phase 3 trial of Caplyta in bipolar I mania met primary and key secondary endpoints, with clinically meaningful improvements in manic symptoms versus placebo, supporting a planned U.S. regulatory filing. The readout strengthens…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe success strengthens Johnson & Johnson's neuroscience pipeline.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The second Phase 3 trial of Caplyta in bipolar I mania met primary endpoints.
  2. 02Johnson & Johnson plans a U.S. regulatory filing.
  3. 03Fresh blood cancer data are also expected.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.